Ad
CCXI Quote Trading Chart ChemoCentryx Inc.
home / stock / ccxi / ccxi quote
Quote | ChemoCentryx Inc. (NASDAQ:CCXI)
| Last: | $51.99 |
|---|---|
| Change Percent: | 0.0% |
| Open: | $0 |
| Close: | $51.99 |
| High: | $0 |
| Low: | $0 |
| Volume: | 113 |
| Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
CCXI Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $51.99 | $0 | $51.99 | $0 | $0 | 113 | 11-02-2022 |
| $51.99 | $0 | $51.99 | $0 | $0 | 8 | 11-01-2022 |
| $51.99 | $51.98 | $51.99 | $52 | $51.98 | 2,480,366 | 10-19-2022 |
| $51.96 | $51.97 | $51.96 | $51.985 | $51.95 | 953,467 | 10-18-2022 |
| $51.98 | $51.94 | $51.98 | $51.98 | $51.93 | 733,281 | 10-17-2022 |
| $51.94 | $51.94 | $51.94 | $51.96 | $51.93 | 629,086 | 10-14-2022 |
| $51.94 | $51.91 | $51.94 | $51.95 | $51.9 | 933,386 | 10-13-2022 |
| $51.95 | $51.88 | $51.95 | $51.95 | $51.87 | 891,178 | 10-12-2022 |
| $51.92 | $51.84 | $51.92 | $51.92 | $51.84 | 846,625 | 10-11-2022 |
| $51.85 | $51.85 | $51.85 | $51.88 | $51.83 | 463,700 | 10-10-2022 |
| $51.86 | $51.83 | $51.86 | $51.88 | $51.82 | 715,881 | 10-07-2022 |
| $51.85 | $51.84 | $51.85 | $51.87 | $51.83 | 756,806 | 10-06-2022 |
| $51.89 | $51.82 | $51.89 | $51.9 | $51.78 | 723,027 | 10-05-2022 |
| $51.87 | $51.84 | $51.87 | $51.89 | $51.8 | 945,475 | 10-04-2022 |
| $51.82 | $51.7 | $51.82 | $51.88 | $51.66 | 1,250,809 | 10-03-2022 |
| $51.66 | $51.67 | $51.66 | $51.79 | $51.66 | 1,046,910 | 09-30-2022 |
| $51.66 | $51.68 | $51.66 | $51.74 | $51.6 | 1,837,071 | 09-29-2022 |
| $51.68 | $51.65 | $51.68 | $51.755 | $51.64 | 1,325,537 | 09-28-2022 |
| $51.64 | $51.65 | $51.64 | $51.77 | $51.5965 | 927,802 | 09-27-2022 |
| $51.62 | $51.63 | $51.62 | $51.76 | $51.61 | 1,351,664 | 09-26-2022 |
News, Short Squeeze, Breakout and More Instantly...
ChemoCentryx Inc. Company Name:
CCXI Stock Symbol:
NASDAQ Market:
0.0% G/L:
$51.99 Last:
113 Volume:
$0 Open:
$51.99 Close:
ChemoCentryx Inc. Website:
Ad
-
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...